Company news: Pfizer and Bristol-Myers Squibb

Share this article:

The FDA granted priority review status to Eliquis (apixaban), the novel oral anticoagulant being developed by Pfizer and Bristol-Myers Squibb, the firms said. The PDUFA goal date for a decision by the FDA is March 28, 2012.

The FDA issued a draft Blueprint for educating doctors on opioid drugs including long-acting and extended-release brand name and generic products. The blueprint contains core messages intended for use by continuing education providers to develop educational materials to train prescribers under the required risk evaluation and mitigation strategy (REMS) for these products. The FDA is seeking stakeholder input on the document until December 7.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions